<DOC>
	<DOCNO>NCT01525589</DOCNO>
	<brief_summary>A Clinical Trial PM01183 Metastatic Breast Cancer assess antitumor activity PM01183 , evaluate whether presence know germline mutation BRCA 1/2 predicts response PM01183 Metastatic Breast Cancer ( MBC ) patient , evaluate safety profile PM01183 analyze pharmacokinetics ( PK ) PK/PD ( pharmacokinetic/pharmacodynamic ) correlation evaluate pharmacogenomic ( PGx ) expression profile tumor sample .</brief_summary>
	<brief_title>A Phase II Clinical Trial PM01183 BRCA 1/2-Associated Unselected Metastatic Breast Cancer</brief_title>
	<detailed_description>A Multicenter Phase II Clinical Trial PM01183 BRCA 1/2-Associated Unselected Metastatic Breast Cancer assess antitumor activity PM01183 term overall response rate ( ORR ) , duration response ( DR ) , clinical benefit [ ORR stable disease last three month ( SD &gt; 3 month ) ] , progression free survival ( PFS ) , one-year overall survival ( 1y-OS ) evaluate whether presence know germline mutation BRCA 1/2 predicts response PM01183 MBC patient , explore activity PM01183 specific breast cancer subpopulation accord hormonal receptor status , HER-2 overexpression , number and/or type prior therapy , accord available histological/molecular classification , evaluate safety profile PM01183 administration schedule [ Day 1 every three week ( q3wk ) ] patient population , analyze pharmacokinetics ( PK ) PM01183 patient population , explore PK/PD ( pharmacokinetic/ pharmacodynamic ) correlation , applicable evaluate pharmacogenomic ( PGx ) expression profile select putative marker potentially predictive response PM01183 , tissue tumor sample .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Women ≥ 18 ≤ 75 year age . Voluntary sign informed consent form ( ICF ) . Proven diagnosis metastatic breast cancer ( MBC ) . At least one , three , prior chemotherapy regimen MBC . Patients know HER2 overexpressing MBC must fail least one prior trastuzumabcontaining regimen metastatic disease . Disease evaluable response specific appropriate criterion . No minimal diseaserelated symptom affect patient daily activity . Adequate major organ function ( normal minimal alteration liver , kidney , hematological , metabolic cardiac function ) Wash period prior Day 1 Cycle 1 : At least three week since last chemotherapy ( six week particular case ) At least four week since last radiotherapy ( RT ) &gt; 30 Gy ) At least one week since last hormonal therapy At least two week since last biological/investigational therapy Minimal ongoing toxicity immediately prior therapy accord specific appropriate criterion . Mild ongoing toxicity allow case alopecia , skin toxicity , fatigue and/or finger numbness tumble . Patients childbearing potential must agree use medically approve contraception method least six week last study drug administration . Known deleterious germline mutation BRCA1/2 ( Patients Cohorts A A1 ) Prior treatment PARP inhibitor ( Patients Cohort A1 ) Prior treatment PM01183 trabectedin . Extensive prior RT . Prior concurrent malignant disease unless cure five year . Exceptions breast cancer breast . Uncommon rare subtypes breast cancer . Symptomatic progressive brain metastasis . Bonelimited exclusively metastases . Relevant diseases clinical situation may increase patient 's risk : History cardiac disease . Moderate breathe difficulty oxygen requirement Active uncontrolled infection . Unhealed wound presence external drainage . Chronically active viral hepatitis . Immunocompromised patient , include know infected human immunodeficiency virus ( HIV ) . Known muscular disease functional alteration Pregnant breastfeeding woman . Impending need immediate RT symptomatic relief . Limitation patient 's ability comply treatment followup protocol .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>PM01183</keyword>
	<keyword>lurbinectedin</keyword>
	<keyword>Pharma Mar</keyword>
</DOC>